Business
AstraZeneca prices a €1.4bn bond offering
AstraZeneca prices a €1.4bn bond offering.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n\n \n30 July 2024 07:00 BST\n \n \nAstraZeneca prices €1.4 billion bond offering\n \n \nAstraZeneca PLC (the Company) announces that, on 29 July 2024, its wholly owned subsidiary AstraZeneca Finance LLC, successfully priced two tranches of Eurobonds totalling €1.4 billion (the Offering). The Offering is expected to close on 5 August 2024, subject to customary closing conditions.\n \nThe Offering consisted of the following notes, issued by AstraZeneca Finance LLC and fully and unconditionally guaranteed by the Company:\n \n· €650 million of fixed rate notes with a coupon of 3.121% maturing on 5 August 2030; and\n· €750 million of fixed rate notes with a coupon of 3.278% maturing on 5 August 2033 (together, the Notes).\n \nThe Company expects to use the net proceeds of the offering for general corporate purposes.\n \nBNP Paribas, Goldman Sachs International, Morgan Stanley and Société Générale acted as joint book-running managers on the transaction.\n \nThe Notes will be issued under the US$10,000,000,000 EMTN programme of the Company and AstraZeneca Finance LLC and admitted to listing on the UK Financial Conduct Authority's Official List and to trading on the London Stock Exchange's Main Market.\n \nThe Notes have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration.\n \nThis announcement shall not constitute an offer to sell or the solicitation of an offer to buy the Notes described herein, nor shall there be any sale of these Notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.\n \n \nAstraZeneca \nAstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and f...